Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates
Abstract
Summary A Bayesian sequential dose‐finding procedure based on bivariate (efficacy, toxicity) outcomes that accounts for patient covariates and dose‐covariate interactions is presented. Historical data are used to obtain an informative prior on covariate main effects, with uninformative priors assumed for all dose effect parameters. Elicited limits on the probabilities of efficacy and toxicity for each of a representative set of covariate vectors are used to construct bounding functions that determine the acceptability of each dose for each patient. Elicited outcome probability pairs that are equally desirable for a reference patient are used to define two different posterior criteria, either of which may be used to select an optimal covariate‐specific dose for each patient. Because the dose selection criteria are covariate specific, different patients may receive different doses at the same point in the trial, and the set of eligible patients may change adaptively during the trial. The method is illustrated by a dose‐finding trial in acute leukemia, including a simulation study.
Citing Literature
Number of times cited according to CrossRef: 47
- Gary Middleton, Kristian Brock, Joshua Savage, Rhys Mant, Yvonne Summers, John Connibear, Riyaz Shah, Christian Ottensmeier, Paul Shaw, Siow-Ming Lee, Sanjay Popat, Colin Barrie, Gloria Barone, Lucinda Billingham, Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial, The Lancet Respiratory Medicine, 10.1016/S2213-2600(20)30033-3, (2020).
- Yifei Zhang, Sha Cao, Chi Zhang, Ick Hoon Jin, Yong Zang, A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes, Biometrics, 10.1111/biom.13347, 0, 0, (2020).
- Xinyang Huang, Jin Xu, Estimating individualized treatment rules with risk constraint, Biometrics, 10.1111/biom.13232, 0, 0, (2020).
- S Kaneko, A Hirakawa, Y Kakurai, C Hamada, A dose-finding approach for genomic patterns in phase I trials, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2020.1744619, (1-20), (2020).
- Takashi Daimon, Akihiro Hirakawa, Shigeyuki Matsui, Takashi Daimon, Akihiro Hirakawa, Shigeyuki Matsui, Designs Considering Toxicity and Efficacy, Dose-Finding Designs for Early-Phase Cancer Clinical Trials, 10.1007/978-4-431-55585-8_5, (95-120), (2019).
- I. Domenicano, S. Ventz, M. Cellamare, R. H. Mak, L. Trippa, Bayesian uncertainty‐directed dose finding designs, Journal of the Royal Statistical Society: Series C (Applied Statistics), 10.1111/rssc.12355, 68, 5, (1393-1410), (2019).
- Kristian Brock, Lucinda Billingham, Christina Yap, Gary Middleton, A Phase II Clinical Trial Design for Associated Co-primary Efficacy and Toxicity Outcomes with Baseline Covariates, Bayesian Statistics and New Generations, 10.1007/978-3-030-30611-3_13, (125-133), (2019).
- Samuel I. Watson, Jo Sartori, Olalekan Uthman, Richard J. Lilford, Health effects of sanitation facilities: a Bayesian semiparametric analysis of compositional data, Journal of the Royal Statistical Society: Series C (Applied Statistics), 10.1111/rssc.12339, 68, 4, (1149-1166), (2019).
- Margot Selosse, Julien Jacques, Christophe Biernacki, Florence Cousson‐Gélie, Analysing a quality‐of‐life survey by using a coclustering model for ordinal data and some dynamic implications, Journal of the Royal Statistical Society: Series C (Applied Statistics), 10.1111/rssc.12365, 68, 5, (1327-1349), (2019).
- Philip G. Sansom, Daniel B. Williamson, David B. Stephenson, State space models for non‐stationary intermittently coupled systems: an application to the North Atlantic oscillation, Journal of the Royal Statistical Society: Series C (Applied Statistics), 10.1111/rssc.12354, 68, 5, (1259-1280), (2019).
- Arnab Kumar Maity, Raymond J. Carroll, Bani K. Mallick, Integration of survival and binary data for variable selection and prediction: a Bayesian approach, Journal of the Royal Statistical Society: Series C (Applied Statistics), 10.1111/rssc.12377, 68, 5, (1577-1595), (2019).
- James Y. Dai, Michael LeBlanc, Case‐only trees and random forests for exploring genotype‐specific treatment effects in randomized clinical trials with dichotomous end points, Journal of the Royal Statistical Society: Series C (Applied Statistics), 10.1111/rssc.12366, 68, 5, (1371-1391), (2019).
- Book Reviews, Journal of the American Statistical Association, 10.1080/01621459.2019.1598212, 114, 525, (477-483), (2019).
- Juhee Lee, Peter F. Thall, Katy Rezvani, Optimizing natural killer cell doses for heterogeneous cancer patients on the basis of multiple event times, Journal of the Royal Statistical Society: Series C (Applied Statistics), 10.1111/rssc.12271, 68, 2, (461-474), (2018).
- Kristen M. Cunanan, Joseph S. Koopmeiners, Efficacy/toxicity dose-finding using hierarchical modeling for multiple populations, Contemporary Clinical Trials, 10.1016/j.cct.2018.06.012, 71, (162-172), (2018).
- Kentaro Takeda, Masataka Taguri, Satoshi Morita, BOIN‐ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes, Pharmaceutical Statistics, 10.1002/pst.1864, 17, 4, (383-395), (2018).
- Md. Moniruzzaman Moni, M. Iftakhar Alam, Patient-specific dose finding in phase I clinical trials, Journal of Applied Statistics, 10.1080/02664763.2018.1428735, 45, 14, (2607-2618), (2018).
- F Yan, P F Thall, K H Lu, M R Gilbert, Y Yuan, Phase I–II clinical trial design: a state-of-the-art paradigm for dose finding, Annals of Oncology, 10.1093/annonc/mdx795, 29, 3, (694-699), (2017).
- Yuanjia Wang, Haoda Fu, Donglin Zeng, Learning Optimal Personalized Treatment Rules in Consideration of Benefit and Risk: With an Application to Treating Type 2 Diabetes Patients With Insulin Therapies, Journal of the American Statistical Association, 10.1080/01621459.2017.1303386, 113, 521, (1-13), (2017).
- P. S. Boonstra, T. M. Braun, J. M. G. Taylor, K. M. Kidwell, E. L. Bellile, S. Daignault, L. Zhao, K. A. Griffith, T. S. Lawrence, G. P. Kalemkerian, M. J. Schipper, Statistical controversies in clinical research: building the bridge to phase II—efficacy estimation in dose-expansion cohorts, Annals of Oncology, 10.1093/annonc/mdx045, 28, 7, (1427-1435), (2017).
- M. Iftakhar Alam, Barbara Bogacka, D. Stephen Coad, Pharmacokinetically guided optimum adaptive dose selection in early phase clinical trials, Computational Statistics & Data Analysis, 10.1016/j.csda.2017.02.009, 111, (183-202), (2017).
- Xuezhou Mao, Ying Kuen Cheung, Sequential designs for individualized dosing in phase I cancer clinical trials, Contemporary Clinical Trials, 10.1016/j.cct.2016.08.018, 63, (51-58), (2017).
- Satoshi Morita, Peter F. Thall, Kentaro Takeda, A simulation study of methods for selecting subgroup‐specific doses in phase 1 trials, Pharmaceutical Statistics, 10.1002/pst.1797, 16, 2, (143-156), (2017).
- Hartmut Döhner, Elihu Estey, David Grimwade, Sergio Amadori, Frederick R. Appelbaum, Thomas Büchner, Hervé Dombret, Benjamin L. Ebert, Pierre Fenaux, Richard A. Larson, Ross L. Levine, Francesco Lo-Coco, Tomoki Naoe, Dietger Niederwieser, Gert J. Ossenkoppele, Miguel Sanz, Jorge Sierra, Martin S. Tallman, Hwei-Fang Tien, Andrew H. Wei, Bob Löwenberg, Clara D. Bloomfield, Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel, Blood, 10.1182/blood-2016-08-733196, 129, 4, (424-447), (2016).
- Mark R. Conaway, Nolan A. Wages, Designs for phase I trials in ordered groups, Statistics in Medicine, 10.1002/sim.7133, 36, 2, (254-265), (2016).
- Beibei Guo, Ying Yuan, Bayesian Phase I/II Biomarker-Based Dose Finding for Precision Medicine With Molecularly Targeted Agents, Journal of the American Statistical Association, 10.1080/01621459.2016.1228534, 112, 518, (508-520), (2016).
- Juhee Lee, Peter F. Thall, Yuan Ji, Peter Müller, Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and Toxicity, Journal of the American Statistical Association, 10.1080/01621459.2014.926815, 110, 510, (711-722), (2015).
- Nolan A. Wages, Paul W. Read, Gina R. Petroni, A Phase I/II adaptive design for heterogeneous groups with application to a stereotactic body radiation therapy trial, Pharmaceutical Statistics, 10.1002/pst.1686, 14, 4, (302-310), (2015).
- Jay Bartroff, Tze Leung Lai, Balasubramanian Narasimhan, A new approach to designing phase I‐II cancer trials for cytotoxic chemotherapies, Statistics in Medicine, 10.1002/sim.6124, 33, 16, (2718-2735), (2014).
- Elihu H. Estey, Controversies Related to Oncology Clinical Trial Development, Cancer Consult: Expertise for Clinical Practice, 10.1002/9781118589199, (831-834), (2014).
- Oleksandr Sverdlov, Weng Kee Wong, Novel Statistical Designs for Phase I/II and Phase II Clinical Trials With Dose-Finding Objectives, Therapeutic Innovation & Regulatory Science, 10.1177/2168479014523765, 48, 5, (601-612), (2014).
- Joanna M Wardlaw, Veronica Murray, Eivind Berge, Gregory J del Zoppo, Thrombolysis for acute ischaemic stroke, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD000213.pub3, (2014).
- I. Das, S. Mukhopadhyay, H. Xu, Individualized Dosing for Multiple Ordered Groups of Patients, Journal of Statistical Theory and Practice, 10.1080/15598608.2013.756348, 7, 1, (95-106), (2013).
- Min Qian, Inbal Nahum-Shani, Susan A. Murphy, Dynamic Treatment Regimes, Modern Clinical Trial Analysis, 10.1007/978-1-4614-4322-3, (127-148), (2013).
- J.M. McGree, C.C. Drovandi, M.H. Thompson, J.A. Eccleston, S.B. Duffull, K. Mengersen, A.N. Pettitt, T. Goggin, Adaptive Bayesian compound designs for dose finding studies, Journal of Statistical Planning and Inference, 10.1016/j.jspi.2011.12.029, 142, 6, (1480-1492), (2012).
- Peter Thall, Hoang Nguyen, Aniko Szabo, Adaptive Decision Making Based on Interval-Censored Data in a Clinical Trial to Optimize Rapid Treatment of Stroke, Interval-Censored Time-to-Event Data, 10.1201/b12290-16, (2012).
- Takashi Daimon, The Continual Reassessment Method (CRM) and Related Topics^|^mdash;A Review. Part II: Modified/Extended CRMs and Related Designs., Japanese Journal of Biometrics, 10.5691/jjb.33.31, 33, 1, (31-76), (2012).
- Peter F. Thall, Hoang Q. Nguyen, Adaptive Randomization to Improve Utility-Based Dose-Finding with Bivariate Ordinal Outcomes, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2012.676586, 22, 4, (785-801), (2012).
- Guanghan F. Liu, A note on effective sample size for constructing confidence intervals for the difference of two proportions, Pharmaceutical Statistics, 10.1002/pst.540, 11, 2, (163-169), (2012).
- Tze L. Lai, Philip W. Lavori, Innovative Clinical Trial Designs, Statistics in Biosciences, 10.1007/s12561-011-9042-5, 3, 2, (145-168), (2011).
- Ying Cheung, References, Dose Finding by the Continual Reassessment Method, 10.1201/b10783-19, (179-186), (2011).
- Peter F. Thall, Aniko Szabo, Hoang Q. Nguyen, Catherine M. Amlie‐Lefond, Osama O. Zaidat, Optimizing the Concentration and Bolus of a Drug Delivered by Continuous Infusion, Biometrics, 10.1111/j.1541-0420.2011.01580.x, 67, 4, (1638-1646), (2011).
- Satoshi Morita, Application of the continual reassessment method to a phase I dose‐finding trial in Japanese patients: East meets West, Statistics in Medicine, 10.1002/sim.3999, 30, 17, (2090-2097), (2011).
- Elihu Estey, New Designs for Clinical Trials: Acute Myeloid Leukemia as an Example, Leukemias: Principles and Practice of Therapy, 10.1002/9781444327359, (419-428), (2011).
- Xiaoyin (Frank) Fan, Chris A. Assaid, Yang (Joy) Ge, Tony W. H. Ho, A Two-Stage Adaptive Design in Phase 2 Clinical Trials for Acute Treatment of Migraine, Drug Information Journal, 10.1177/009286151104500311, 45, 3, (315-330), (2011).
- Peter F. Thall, Hoang Q. Nguyen, Shein-Chung Chow, Covariate-Adjusted Adaptive Dose-Finding in Early Phase Clinical Trials, Encyclopedia of Biopharmaceutical Statistics, 10.3109/9781439822463, (369-379), (2010).
- Nadine Houede, Peter F. Thall, Hoang Nguyen, Xavier Paoletti, Andrew Kramar, Utility‐Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials, Biometrics, 10.1111/j.1541-0420.2009.01302.x, 66, 2, (532-540), (2010).




